Phathom Pharmaceuticals (PHAT) Q3 2026 earnings review
Phathom's reflux prescriptions rise, but a lawsuit challenges its exclusivity
Phathom Pharmaceuticals, the maker of the acid reflux drug Voquezna, expanded insured prescriptions while holding operating costs steady. Revenue rose 14% from last quarter to $85 million as insured volume climbed 19%, easing fears of an immediate bottleneck after last quarter's outlook cut. Chief executive Steve Basta rolled out a zero-copay programme at quarter-end, and by our math the unchanged full-year plan requires quarterly sales growth to speed up to 18% in the fourth quarter.
| Net revenue | $84.7M +14% from last quarter (+71% from a year ago) |
|---|---|
| Insured prescriptions filled | 248,000 +19% from last quarter (65% of total) |
| Operating profit, excluding stock-based pay | $5.8M up from $2.7M last quarter by our math |
| Full-year revenue outlook | Unchanged middle of the range: $317.5M (+81% growth) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because steady prescription growth was offset by a new legal challenge to Voquezna's regulatory protection and an unchanged full-year plan. Operating profit excluding stock-based pay doubled from last quarter to nearly $6 million by our math, yet cash on hand rose by only $2 million. Meanwhile, a generic drugmaker sued the Food and Drug Administration to overturn Voquezna's May 2032 exclusivity, and the agency opened a public comment docket on the dispute.
The question now is whether the new zero-copay offer speeds up insured prescriptions fast enough to meet the fourth-quarter target and build cash ahead of 2028 debt deadlines. Either insurance hurdles were a workflow issue that the new tools fix, or the easy specialist patients are already treated. Fourth-quarter revenue and the regulatory response after the November 23 comment deadline will tell.
🐂 Bull Case
Insured Prescriptions Grew Through the Access Bottleneck
Phathom sells Voquezna, a stomach acid blocker for acid reflux (GERD). Last quarter the drugmaker cut its full-year sales plan because doctors faced paperwork hurdles getting insurance approval. Chief executive Steve Basta said the group launched "several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-class GERD treatment".
- Insured prescriptions: 248,000, up 19% from last quarter and 72% from a year ago
- Cash-pay prescriptions: 132,000, up 14% from last quarter by our math (though the text states 6%)
- Net revenue: $84.7 million, up 14% from last quarter and 71% from a year ago (62% excluding an accounting change by our math)
This matters because insured prescriptions carry the main revenue stream and grew faster than cash-pay volume, lifting the insured share to 65%. That argues against a sudden ceiling on demand, but one quarter does not settle the concern because the full-year outlook did not move.
What to watch: fourth-quarter revenue against the $100.2 million implied by the middle of the full-year outlook. Clearing that mark would show the new access tools accelerated sales.
Sales Gains Brought Operating Profit Near Break-Even
Since mid-2025 Phathom has focused its sales reps on digestive specialists rather than general doctors to control spending as prescriptions grow. That shift kept marketing and administrative overhead (SG&A) rising much slower than revenue this quarter.
SG&A fell by 36.1 percentage points of revenue from a year ago to 68.1%, while research and development costs fell by 3.9 points to 10.3%. Gross margin dropped 9.2 points to 78.3% because Phathom moved certain third-party fees from revenue deductions into cost of goods this year. Even so, operating loss narrowed from $15.3 million to $85,000, and operating profit excluding stock-based pay more than doubled from last quarter to $5.8 million by our math.
What to watch: fourth-quarter operating expenses excluding stock-based pay against the $66.8 million implied by the full-year outlook. Staying below that level would protect the new profit cushion.
Two Clinical Trials Advance Toward New Uses
Phathom is testing Voquezna in two additional conditions to expand its addressable market beyond daily acid reflux treatment. On September 29 the drugmaker dosed the first patient in a late-stage (Phase 3) study for as-needed reflux relief, slightly ahead of its fourth-quarter target.
The company also confirmed it will report results this quarter from a mid-stage (Phase 2) study in eosinophilic esophagitis (EoE), an allergic swallowing disorder. Success in EoE matters because it could open a second specialty market and support a pediatric study that adds six months of regulatory protection.
What to watch: the 12-week EoE study readout before year-end. A clear reduction in throat inflammation would allow late-stage trial planning in 2027.
🐻 Bear Case
A Generic Rival Challenged Voquezna's Patent Shield
Phathom relies on a 2025 US Food and Drug Administration (FDA) ruling that protects Voquezna tablets from generic copies until May 2032. That ruling had settled earlier doubts about how long the company would own the market alone.
This month a federal court allowed Phathom to join a lawsuit that generic drugmaker BDR Pharmaceuticals filed against the FDA to overturn that 2032 protection. A second generic applicant was also referenced in the release, and on October 23 the FDA opened a public comment period on the legal dispute running through November 23. Phathom said it will "vigorously defend its statutory exclusivities".
The reopened regulatory docket matters because Voquezna generates all of Phathom's revenue. If the agency modifies or reverses its prior decision after reviewing public comments, generic versions could enter the market years earlier than planned.
What to watch: the FDA action following the November 23 comment deadline. Any move by the agency to reconsider the May 2032 protection date would shorten the commercial window.
Cash Generation Still Trails the Debt Schedule
"Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter," finance chief Sanjeev Narula said. The drugmaker raised equity in January and reworked its loan in February, and it repeated that cash on hand and future cash flow will be "sufficient to invest in its business and satisfy all outstanding debt obligations without requiring additional debt or equity financing".
The balance sheet shows why that claim remains tight. Cash rose by $2.1 million from last quarter to $184.6 million, while total interest expense was $15.4 million ($4.4 million excluding non-cash items by our math) and total liabilities climbed by $21.3 million to $692.7 million. Because Phathom faces a 2028 deadline to satisfy its $275 million royalty financing minimum alongside term loan payments starting in 2028, adding $2 million of cash a quarter is not yet rapid enough.
What to watch: quarterly cash accumulation in the fourth quarter and across 2027. Cash generation must rise substantially to cover the 2028 payment schedule without new financing.
Risks this quarter didn't answer
Four standing concerns and watch items were not updated in the third-quarter earnings release.
- New-to-brand prescription share among top digestive doctors: absent from the release for a second quarter; the conference call or quarterly filing may show if new patient conversion slowed.
- Quarterly price discounts and rebates (gross-to-net): only the unchanged 55–59% full-year range appeared; the quarterly filing will show whether third-quarter rebates rose.
- Competing acid blocker launch: expected around early 2027; 2027 insurance formulary updates will show whether payers use a second drug to demand higher rebates.
- Single-product and supplier reliance: all sales come from vonoprazan licensed from Takeda; the quarterly filing will update milestone and supply commitments.
👓 Other Themes
Zero-Copay Offer Launched to Speed Approvals
At the end of the third quarter Phathom introduced a new copay offer through its pharmacy partner BlinkRx that lets eligible insured patients pay as little as $0 for Voquezna. The company also rolled out "Access First" materials to help doctors navigate insurance rules. Because the zero-copay programme started at the end of September, its effect on fill rates and rebate costs will only show in fourth-quarter numbers.
💲 Other KPIs
Dipped 2.4% from $229 last quarter by our math, as total prescriptions grew 17% while net revenue rose 14%. Over the last four quarters the blended average has stayed between $211 and $229 per filled prescription, which keeps revenue moving closely with prescription volume.
Up 15.7% from 73.4 million a year ago and up 1.4% from 83.7 million last quarter. The increase came from the January 2026 stock offering that raised $122 million to pay down debt, which spreads future earnings across more shares.
Rose 3.2% from $671.3 million in June, though still slightly below $697.3 million at the end of 2025. The balance rises each quarter because Phathom records $10.0 million of non-cash interest on its revenue-sharing debt above the cash royalty it pays.
🔮 Guidance
Unchanged. The plan calls for 81% full-year growth at the middle of the range (71% excluding the accounting reclassification by our math), after Phathom lowered the target by $15 million last quarter. By our math, that leaves $100.2 million for the fourth quarter, requiring sequential sales growth to speed up from 14% in Q3 to 18% in Q4.
Unchanged. The full-year spending plan still sits 15% below 2025 levels at the middle of the range. By our math, after spending $173.2 million across the first nine months, the outlook leaves $66.8 million for the fourth quarter, a 10% step-up from Q3 as clinical trial work expands.
Unchanged. The drugmaker kept its full-year target for insurance rebates and pharmacy discounts at 55% to 59% of gross sales. Phathom previously noted that discounts landed in the lower half of the band during the first half and would rise moderately in the second half.
Unchanged. The full-year target stays near 80%. Third-quarter gross margin dipped to 78.3% from 79.7% in the second quarter, bringing the nine-month average to 79.1% by our math.
❓ Key Questions
Why Did Cash-Pay Prescription Growth Differ From Prior Tables?
The release states cash-pay prescriptions grew 6% from last quarter to 132,000, but second-quarter cash-pay volume was reported as 116,000, which is a 14% increase by our math. Was the second-quarter figure revised, or did channel definitions change?
What Was Voquezna's Share of New Prescriptions in Q3?
In the first quarter Phathom highlighted a 45% share of new prescriptions among its top 300 digestive specialists, then omitted the figure in Q2 and in today's release. Did new-patient share among core specialists rise or fall in Q3?
How Much Will the $0 Copay Offer Raise Rebate Costs?
Phathom launched a $0 copay offer through BlinkRx at the end of September while keeping its 55–59% full-year discount outlook. How much extra discount per prescription does the $0 copay carry in the fourth quarter?
Can the FDA Change Voquezna's 2032 Exclusivity After November 23?
The FDA opened a public comment period through November 23 inside the BDR Pharmaceuticals lawsuit challenging Voquezna's May 2032 protection. What is the procedural timeline after comments close, and has the FDA stayed its 2025 decision?